Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent ...
Primary results from the Phase II ARACOG (AFT-47) trial, a head-to-head randomized trial conducted by Alliance Foundation Trials LLC, showed that patients treated with NUBEQA® (darolutamide; n=55) ...
Over a month ago, I was on Instagram when I saw a video of a scientist who said, “They put the blood of people exercising on ...
(NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...
The show of hands at this year's ASCO annual meeting is unmistakable. BioNTech is presenting more than 25 clinical studies in Chicago, including 13 pivotal trials — an extraordinary concentration of ...
The Punch on MSN
Eating disorders among female adolescents
On this page in the past, we have looked at the problem of difficulties with feeding of various types affecting several age brackets. We also discussed the fact that some of these problems underscore ...
The Sunday Guardian Live on MSN
Remembering the last Maharani of Travancore
India, May 31 -- An intimate portrait recalls Travancore's last Maharani through family memories, rituals, grief, discipline, and enduring affection.
Summit Therapeutics Inc. today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer (mCRC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results